Scientists from an international consortium led by Dr. Eduard Batlle, head of the Colorectal Cancer laboratory at IRB Barcelona, ICREA researcher and group leader of CIBER de Cáncer (CIBERONC), together with the Dutch company ...
Apr 25, 2022
0
68
As cancer therapy has advanced, the complexity of oncology has become apparent. There are many moving parts in a cell that can malfunction leading to a cancerous path, one example being epidermal growth factor receptors (EGFR)—a ...
Apr 22, 2022
0
24
The various manifestations of head and neck carcinomas rank sixth in frequency worldwide and are fatal for about half a million people every year. In a quarter of cases, head and neck squamous cell carcinoma (HNSCC) is caused ...
Apr 19, 2022
0
17
A cancer diagnosis is scary. Some doctors say it's time to rename low-grade prostate cancer to eliminate the alarming C-word.
Apr 18, 2022
0
148
Hepatocellular carcinoma (HCC) is the most primary liver cancer. It is one of the most common and deadly cancer worldwide, especially in East Asia. Advanced HCC patients expect a significantly low 5-year survival rate as ...
Apr 18, 2022
0
2
Scientists at UCL have significantly boosted the effectiveness of a therapeutic vaccine designed to control chronic hepatitis B (HBV) infection, after uncovering and thwarting 'the enemy within'.
Apr 13, 2022
0
62
Hundreds of chemical compounds were screened on cell cultures representing different stages and subtypes of bladder cancer and several promising agents with inhibitory (growth-inhibiting) effects were identified. A drug used ...
Apr 11, 2022
0
21
San Diego startup AltheaDx, which developed a molecular test designed to guide therapy for depression and anxiety based on a patient's genetics, is being acquired for $65 million in stock and cash.
Apr 7, 2022
0
3
A new paper in Nature Communications reveals new insights into adaptations made by cancer cells to rewire their metabolism to achieve growth and survive. Among the discoveries include a challenge to a well-known feature in ...
Mar 23, 2022
0
8
Patients treated for Merkel cell carcinoma (MCC) face a five-year recurrence rate of 40%—markedly higher than the recurrence rates for melanoma and other skin cancers, according to research published today in JAMA Dermatology.
Feb 23, 2022
0
1
